Vonjo

Adults with intermediate or high-risk myelofibrosis with platelet count below 50x10^9/L.

200 mg orally twice daily with or without food.

Capsules: 100 mg

Concomitant use of strong CYP3A4 inhibitors or inducers.

• Hemorrhage: Assess bleeding risk; withhold for Grade 3+ bleeding.
• Diarrhea: Dose interrupt if Grade 3+.
• Thrombocytopenia: Monitor CBCs.
• QTc Prolongation: Monitor ECGs.
• Major Adverse Cardiac Events: Reported with JAK inhibitors.

Diarrhea (48%), Thrombocytopenia (34%), Nausea (32%), Anemia (24%), Peripheral Edema (18%), Vomiting (16%)

Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.

Strong CYP3A4 Inhibitors: Contraindicated.
Strong CYP3A4 Inducers: Contraindicated.

Consult the full prescribing information for pregnancy-related considerations.

Refer to prescribing information for lactation guidance.

Pediatric safety and efficacy information is detailed in the full label.

Dose modifications for organ impairment are specified in the complete prescribing information.

Pacritinib inhibits JAK2 (including V617F) and FLT3. Unlike ruxolitinib, it has limited JAK1 activity, potentially causing less immunosuppression and myelosuppression in cytopenic patients.

Tmax: 4-8 hours. Protein binding: >99%. Metabolized by CYP3A4.

Clinical efficacy and safety data supporting the approval are available in the full prescribing information and from the clinical trials listed below.

• PERSIST-2 — Pacritinib vs BAT in myelofibrosis with platelets <100K. Phase III, n=311.
  🔬 NCT02055781 ↗

Consult the prescribing information for complete indication details and associated tumor types.